This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. A common first reaction to crowdfunding for life sciences may be to dismiss it out of hand. Given the undeniable chill in early stage funding, it is worth giving the […]
This infographic shows the pharmaceutical companies that listed the most patents last year. The companies with the most drug patents listed last year are Novartis, Lilly, Merck,Allergan, Sanofi Aventis Us, Astrazeneca, Glaxosmithkline, Pfizer, Veroscience, andWatson Labss. For more infographics, see the DrugPatentWatch Pharmaceutical Innovation Infographics. Do you have a response to this infographic? Respond in the comments section below.
These infographics from DrugPatentWatch.com and BiologicPatentWatch.com track innovation and patent activity in the pharmaceutical and biotechnology industries: Pharmaceutical Innovation Infographics Which Drugs Face Patent Expirations this Month? What are the Top-selling Drugs? How Many Drug Patents Will Expire in the Coming Months? How Many Drug Patents Will Expire in the Coming Years? Which Drugs Have the […]
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
Go to paperABSTRACT: The two leading therapeutic areas for biological products, in t…
This is a guest post by Morrison & Foerster‘s Marc A. Hearron, James J. Mullen, III and Matthew I. Kreeger. Do you have a response to this post? Sound off in the comments section below. The Supreme Court of the United States recently heard oral argument in Association for Molecular Pathology v. Myriad Genetics, Inc. (No. 12-398) to […]
I will be at BIO 2013, representing BiotechBlog, the Journal of Commercial Biotechnology, and Scientific American Worldview. I look forward to meeting new and existing readers. If you have an interest in guest-posting on BiotechBlog, an interest in submitting a paper to the Journal of Commercial Biotechnology, or have perspectives on global biotechnlogy that may […]
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for March 25 2013
DrugPatentWatch Serves Your Competitive Intelligence
|
|||||||||||||||||||||||||
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for March 22 2013
DrugPatentWatch Serves Your Competitive Intelligence
|
|||||||||||||||||||||
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The SEC’s enforcement programme on biotechnology’s communications with the investment community
Go to paperABSTRACT: The proliferation of biotechnology star…
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Even if you have never heard of Thomas Kuhn, your thinking about science has most likely been effected by his theory of what causes paradigm shifts. Over 50 years […]
